Copied from IPIX web site: December 11, 2017
Post# of 72447
(Total Views: 254)
Posted On: 12/11/2017 10:44:13 AM
Copied from IPIX web site:
December 11, 2017
Brilacidin-OM Called a “Top Contender” in Oral Mucositis Market
Brilacidin
A recent online article—"A Billion Dollar Market Just Waiting for a New Oral Mucositis Drug”—published by Baystreet.ca favorably mentions Brilacidin-OM as one of five promising drug candidates—the “Top Contenders”—targeting the Oral Mucositis (OM) market.
Innovation Pharmaceuticals has completed its randomized double-blind Phase 2 Trial of Brilacidin-OM (see NCT02324335), with topline results having been released.
Results revealed a clear reduction in the incidence of Severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin-OM as compared to those on placebo. Brilacidin also appeared generally safe and well-tolerated across the full safety population.
The Company is now preparing to move the Brilacidin-OM program forward.
December 11, 2017
Brilacidin-OM Called a “Top Contender” in Oral Mucositis Market
Brilacidin
A recent online article—"A Billion Dollar Market Just Waiting for a New Oral Mucositis Drug”—published by Baystreet.ca favorably mentions Brilacidin-OM as one of five promising drug candidates—the “Top Contenders”—targeting the Oral Mucositis (OM) market.
Innovation Pharmaceuticals has completed its randomized double-blind Phase 2 Trial of Brilacidin-OM (see NCT02324335), with topline results having been released.
Results revealed a clear reduction in the incidence of Severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin-OM as compared to those on placebo. Brilacidin also appeared generally safe and well-tolerated across the full safety population.
The Company is now preparing to move the Brilacidin-OM program forward.
(4)
(0)